A. Forero-Torres

Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma

Anas Younes, A. Forero-Torres, Nancy L. Bartlett et al. · Journal of Clinical Oncology · 2008 · 42 citations

Cell Therapy, Immunology, Immunotherapy +20

TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer.

Jae C. Chang, Ingrid A. Mayer, A. Forero-Torres et al. · Journal of Clinical Oncology · 2011 · 41 citations

High Pcr Rate, Breast Oncology, Rapid Eradication +17

Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: A case series.

Nancy L. Bartlett, Laurie E. Grove, Dana A. Kennedy et al. · Journal of Clinical Oncology · 2010 · 28 citations

Hematological Malignancy, Medicine, Malignant Blood Disorder +15

A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas

MN Saleh, Ivor Percent, Tina E. Wood et al. · Journal of Clinical Oncology · 2008 · 26 citations · Full text

Immunology, Cell Death, Cs- 1008 +18

Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC)

Alison Conlin, C. Hudis, A M Bach et al. · Journal of Clinical Oncology · 2009 · 24 citations

First-line Therapy, Breast Oncology, Adjuvant Chemotherapy +16